Literature DB >> 7890281

An immunohistochemical study of p53 with correlations to histopathological parameters, c-erbB-2, proliferating cell nuclear antigen, and prognosis.

T Haerslev1, G K Jacobsen.   

Abstract

In an immunohistochemical study of 490 primary breast cancer patients with a follow-up period of more than 10 years, we found that p53 was not a prognostic factor for disease-free or overall survival among the whole cohort or among lymph node-positive or -negative patients. In a multiple logistic regression model classical histopathological parameters, such as lymph node status, number of mitoses, histological grade, and absence of progesterone receptors, were independent, poor prognostic predictors. In univeriate analysis p53 immunoreactivity was positively correlated with the absence of tubule formation, high histological grade (poor differentiation), absence of estrogen receptors (ER), and a high proliferating cell nuclear antigen (PCNA) score (ie, parameters indicative of an aggressive phenotype). The lack of prognostic significance may be attributable partly to the method used, because immunohistochemistry underdetects rather than overdetects p53 protein. No correlation between p53 and c-erbB-2-oncoprotein was demonstrated.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7890281     DOI: 10.1016/0046-8177(95)90061-6

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  9 in total

Review 1.  AN OVERVIEW OF PROGNOSTIC MARKERS IN BREAST CANCER.

Authors:  G U Deshpande; Ramji Rai
Journal:  Med J Armed Forces India       Date:  2017-06-26

Review 2.  Prognostic factors in node-negative breast cancer: a review of studies with sample size more than 200 and follow-up more than 5 years.

Authors:  Attiqa N Mirza; Nadeem Q Mirza; Georges Vlastos; S Eva Singletary
Journal:  Ann Surg       Date:  2002-01       Impact factor: 12.969

3.  Coexpression of p53 and c-erbB-2 proteins is associated with histological type, tumour stage, and cell proliferation in malignant salivary gland tumours.

Authors:  N Kamio
Journal:  Virchows Arch       Date:  1996-05       Impact factor: 4.064

Review 4.  P53, apoptosis, and breast cancer.

Authors:  D M Barnes; R S Camplejohn
Journal:  J Mammary Gland Biol Neoplasia       Date:  1996-04       Impact factor: 2.673

5.  CORRELATIONSHIP OF HORMONE RECEPTOR STATUS, p53 MUTATION AND c-erb B-2 OVEREXPRESSION WITH NUCLEAR GRADING IN BREAST CANCERS.

Authors:  Prabal Deb; G U Deshpande; Ramji Rai
Journal:  Med J Armed Forces India       Date:  2017-06-12

6.  Atypical epithelial changes and mutant p53 gene expression in ovarian endometriosis.

Authors:  H Bayramoğlu; E Düzcan
Journal:  Pathol Oncol Res       Date:  2001       Impact factor: 3.201

Review 7.  The clinical significance of p53 aberrations in human tumours.

Authors:  S Bosari; G Viale
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

Review 8.  An overview of prognostic factors for long-term survivors of breast cancer.

Authors:  Isabelle Soerjomataram; Marieke W J Louwman; Jacques G Ribot; Jan A Roukema; Jan Willem W Coebergh
Journal:  Breast Cancer Res Treat       Date:  2007-03-22       Impact factor: 4.872

9.  Effect Modification of Hormonal Therapy by p53 Status in Invasive Breast Cancer.

Authors:  Sei Hyun Ahn; Hwa Jung Kim; Wonshik Han; Jihyoung Cho; Gyungyub Gong; Kyung Hae Jung; Sung-Bae Kim; Byung Ho Son; Jong Won Lee
Journal:  J Breast Cancer       Date:  2013-12-31       Impact factor: 3.588

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.